This article is the second in a five-part series about emerging vaccines for multiple myeloma.  It provides an introduction to the various types of vaccines that are currently under development for myeloma.  The first article in the series provided an introduction to the concept of a myeloma vaccine. The third article describes vaccines for which clinical trials have been completed, the fourth article focuses on ongoing vaccine research, and the fifth article tells the story of…

This article is the first in a five-part series about emerging vaccines for multiple myeloma.  It provides an introduction to the concept of a myeloma vaccine.  The second article provides an introduction to the various types of vaccines that are currently under development for myeloma, the third article describes vaccines for which clinical trials have been completed, the fourth article focuses on ongoing vaccine research, and the fifth article tells the story of a patient who…

The results of a recent Japanese study suggest that a vincristine-doxorubicin-dexamethasone regimen without intermittent high-dose dexamethasone reduces the risk of bacterial infection in multiple myeloma patients without affecting the treatment’s efficacy. 

Based on these findings, the study authors recommended avoiding the administration of intermittent high-dose dexamethasone with the vincristine-doxorubicin-dexamethasone regimen in myeloma patients at high risk for infection. 

The combination treatment of vincristine (Oncovin), doxorubicin (Adriamycin), and dexamethasone (Decadron) plus high-dose pulses of dexamethasone (referred to as…

Results of a recent Canadian study show that the use of novel agents, particularly Velcade and Revlimid, as salvage therapy after stem cell transplantation improves overall survival and post-relapse survival of multiple myeloma patients, including high-risk patients who relapsed early following transplantation.

Although multiple myeloma remains an incurable disease, the introduction of novel agents, such as thalidomide (Thalomid), Velcade (bortezomib), and Revlimid (lenalidomide) has lead to significant improvements in disease outcomes.

In their analysis, the Canadian researchers…

The results of a Phase 1 clinical trial in multiple myeloma patients indicate that total body irradiation using a technique that focuses radiation on the bone marrow is a safe and effective way to prepare the bone marrow for stem cell transplantation. By focusing the radiation on the bone marrow, the researchers were able to limit damage to organs in the body and reduce resulting side effects.

Total body irradiation is commonly used prior to stem cell transplantation to destroy…